Related Experiment Videos
ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer
H U Graber1, H Friess, B Kaufmann
1Department of Visceral and Transplantation Surgery, University of Bern, Switzerland.
Abstract:
The erbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); erbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation. Because the expression of erbB-4 mRNA is generally low in the pancreas, quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to determine the erbB-4 levels in human normal and cancerous pancreatic tissue. Our results show that the mRNA expression of this receptor is 6-fold decreased in the non-metastatic stages of pancreatic cancer when compared to tumors with lymph node or distant metastases or to the normal pancreas. In addition, immunohistochemistry demonstrated that in the normal pancreas, the erbB-4 antigen was predominantly present in the cell membrane and cytoplasm of the ductal and acinar cells and at a much lower level, in islet cells. In pancreatic cancer, 61 of 75 samples exhibited weak to moderate immunoreactivity for erbB-4 in the tumor cells. Moreover, in the peri-tumorous region with chronic pancreatitis-like morphological changes, there was weak-to-moderate erbB-4 immunostaining in small ductules and degenerating acinar cells. Uni- and multivariate survival analyses using as variables age, sex, stage of cancer, histo-pathological grading, and erbB-4 immunoreactivity, revealed a significant effect for stage of cancer (p < 0.01) whereby the risk of dying was 2.3 times higher in patients with metastases than in patients without. However, the level of erbB-4 immunoreactivity in pancreatic cancer cells had no influence on patient survival.
Insights
ErbB-4 mRNA levels are significantly reduced in early-stage pancreatic cancer. This decrease in ErbB-4 expression was observed in non-metastatic pancreatic tumors compared to metastatic ones and normal tissue.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The erbB-4 gene encodes a receptor tyrosine kinase in the epidermal growth factor receptor family.
- erbB-4 interacts with erbB-2, playing a role in cell signaling pathways.
- Pancreatic cancer is characterized by complex molecular alterations, necessitating research into specific gene expressions.
Purpose of the Study:
- To investigate the expression levels of erbB-4 mRNA and protein in normal and cancerous pancreatic tissues.
- To determine the correlation between erbB-4 expression and clinicopathological features, including cancer stage and patient survival.
Main Methods:
- Quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was employed to measure erbB-4 mRNA levels.
- Immunohistochemistry was utilized to assess erbB-4 protein expression in tissue samples.
- Uni- and multivariate survival analyses were performed to evaluate prognostic factors.
Main Results:
- A 6-fold decrease in erbB-4 mRNA expression was observed in non-metastatic pancreatic cancer stages compared to metastatic stages and normal pancreas.
- Immunohistochemistry revealed weak to moderate erbB-4 immunoreactivity in most pancreatic cancer samples and in peri-tumorous regions.
- Cancer stage was a significant prognostic factor, with a 2.3 times higher risk of mortality in patients with metastases, while erbB-4 immunoreactivity did not influence survival.
Conclusions:
- Reduced erbB-4 mRNA expression is associated with early-stage pancreatic cancer.
- While erbB-4 protein is present in pancreatic tumors, its expression level does not appear to impact patient survival.
- Further research is warranted to understand the functional role of erbB-4 in pancreatic carcinogenesis and its potential as a biomarker.